Key Points
- CeriBell CEO Xingjuan Chao sold 31,415 shares at an average price of $25.03, generating $786,317.45. Following the transaction, Chao retained 787,799 shares, a 3.83% reduction in direct ownership.
- CeriBell recently reported a quarterly loss of $0.51 per share, missing estimates by $0.04, though revenue of $28.10 million exceeded analyst expectations. Analysts expect the company to post a full-year loss of $1.96 per share.
- Analyst sentiment remains generally positive, with a consensus “Moderate Buy” rating and recent price-target increases from Canaccord Genuity and BTIG Research; the stock opened at $24.31, near its 52-week high of $25.33.
CeriBell, Inc. (NASDAQ:CBLL - Get Free Report) CFO Scott Blumberg sold 990 shares of the company's stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $25.00, for a total value of $24,750.00. Following the transaction, the chief financial officer owned 148,121 shares of the company's stock, valued at approximately $3,703,025. This represents a 0.66% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
Scott Blumberg also recently made the following trade(s):
- On Wednesday, August 19th, Scott Blumberg sold 33,512 shares of CeriBell stock. The stock was sold at an average price of $25.03, for a total value of $838,805.36.
CeriBell Price Performance
Shares of CBLL opened at $24.31 on Friday. The company has a debt-to-equity ratio of 0.16, a quick ratio of 8.79 and a current ratio of 9.18. The firm's 50-day simple moving average is $19.43 and its two-hundred day simple moving average is $19.19. CeriBell, Inc. has a fifty-two week low of $10.85 and a fifty-two week high of $25.33. The stock has a market cap of $933.02 million, a PE ratio of -13.81 and a beta of 0.81.
CeriBell (NASDAQ:CBLL - Get Free Report) last posted its quarterly earnings results on Monday, August 10th. The company reported ($0.51) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.47) by ($0.04). The company had revenue of $28.10 million during the quarter, compared to analysts' expectations of $27.28 million. CeriBell had a negative return on equity of 44.85% and a negative net margin of 64.73%. Analysts anticipate that CeriBell, Inc. will post -1.96 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently made changes to their positions in the stock. TimesSquare Capital Management LLC acquired a new stake in CeriBell in the second quarter worth about $15,182,000. Royce & Associates LP acquired a new position in shares of CeriBell in the 4th quarter valued at $11,695,000. KCM Capital Inc grew its holdings in CeriBell by 40.0% in the first quarter. KCM Capital Inc now owns 1,400,000 shares of the company's stock valued at $25,662,000 after purchasing an additional 400,000 shares during the period. Kopp Family Office LLC acquired a new position in shares of CeriBell during the 2nd quarter worth about $672,000. Finally, Quantinno Capital Management LP increased its stake in shares of CeriBell by 3.0% in the 1st quarter. Quantinno Capital Management LP now owns 140,347 shares of the company's stock worth $2,573,000 after acquiring an additional 4,119 shares during the last quarter.
Trending Headlines about CeriBell
Here are the key news stories impacting CeriBell this week:
- Positive Sentiment: BTIG raised its price target to $30 and reiterated a Buy rating, signaling confidence in CeriBell’s growth outlook. Canaccord Genuity also raised its target to $26 and maintained a Buy rating. CeriBell Stock Price Expected to Rise, BTIG Research Analyst Says
- Positive Sentiment: Institutional ownership activity was generally constructive, with several firms adding to or initiating small positions in CBLL. Barclays also upgraded the shares to Neutral, while the broader analyst consensus remains “Moderate Buy.”
- Neutral Sentiment: CeriBell’s latest quarter showed mixed results: revenue of $28.10 million exceeded estimates of $27.28 million, but adjusted EPS of negative $0.51 missed the consensus loss estimate of negative $0.47. The company remains unprofitable, with analysts expecting a full-year loss.
- Negative Sentiment: CEO Xingjuan Chao sold 31,415 shares for approximately $786,000 at an average price of $25.03, reducing her ownership by 3.83%. She also sold 2,199 shares the prior day and has made additional sales in recent months. Xingjuan Chao Sells Shares of CeriBell
- Negative Sentiment: CFO Scott Blumberg sold 33,512 shares worth approximately $839,000 and an additional 990 shares, reducing his direct holdings by about 18.45% overall. Multiple senior-executive sales near the stock’s recent highs may reinforce profit-taking concerns and help explain the stock’s decline.
Analyst Upgrades and Downgrades
Several analysts recently issued reports on CBLL shares. Barclays upgraded shares of CeriBell to a "neutral" rating in a research report on Tuesday. Canaccord Genuity Group upped their target price on shares of CeriBell from $25.00 to $26.00 and gave the stock a "buy" rating in a research report on Tuesday, August 11th. BTIG Research raised their target price on shares of CeriBell from $28.00 to $30.00 and gave the company a "buy" rating in a report on Tuesday. Finally, Weiss Ratings upgraded CeriBell from a "sell (e+)" rating to a "sell (d-)" rating in a research report on Thursday, August 13th. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $22.40.
Get Our Latest Stock Report on CeriBell
About CeriBell
(
Get Free Report)
CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell's solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.
The company's product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
